Phase 1b/2a Program Commences for RVX-208

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.("Resverlogix" or the "Company") (TSX: RVX) is pleased to announcethat the Phase 1b/2a program for the study of RVX-208 in subjectswith normal lipids and those with low high-density lipoprotein (HDL)cholesterol has proceeded according to plan.

"We are very excited about moving forward into this important28-day study with RVX-208. Our previous clinical study demonstratedthat RVX-208 was safe, tolerable and had favourablepharmacokinetics," stated Dr. Allan Gordon, Senior Vice PresidentClinical Development of Resverlogix. "This trial will continue toexamine safety and tolerance as well it is a proof of principle studyfor ApoA-I production and HDL functionality. Approximately half ofthe subjects will have low levels of HDL cholesterol, a conditionassociated with significant increased risk of cardiovasculardisease," added Dr. Gordon.

"The ensuing Phase 1b/2a study comprises several novel facets toexpedite the clinical process for RVX-208 and its eventualregistration as a drug," stated Donald J. McCaffrey, President andCEO of Resverlogix. McCaffrey further confirmed, "Along with therequired regulatory provisions that must be addressed such as safety,tolerance and pharmacokinetics, the study also will measure keyreverse cholesterol transport markers which RVX-208 impacts. Theseare exclusive favourable features that make this drug unique amongits competitors."

RVX-208, a novel small molecule therapeutic that facilitatesendogenous ApoA-I production, is positioned to be one of the mostpromising emerging drugs in the treatment of atherosclerosis. To theCompany's knowledge RVX-208 is the only novel small molecule that isspecifically designed to increase ApoA-I production and thereby raiseHDL levels thus enhancing HDL functionality to augment reversecholesterol transport.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged inthe development of novel therapies for important global medicalmarkets with significant unmet needs. The NexVas(TM) program is theCompany's primary focus which is to develop novel small moleculesthat enhance ApoA-I. These vital therapies address the grievousburden of atherosclerosis and other important diseases such as acutecoronary syndrome, diabetes, Alzheimer's disease and other vasculardisorders. The Company's secondary focus is TGF-Beta Shield(TM), aprogram that aims to address burgeoning grievous diseases, such ascancer and fibrosis. Resverlogix Corp. trades on the Toronto StockExchange (TSX:RVX). For further information please visithttp://www.resverlogix.com.

This news release may contain certain forward-looking statementsthat reflect the current views and/or expectations of ResverlogixCorp. with respect to its performance, business and future events.Such statements are subject to a number of risks, uncertainties andassumptions. Actual results and events may vary significantly. TheTSX Exchange does not accept responsibility for the adequacy oraccuracy of this news release.

Website: http://www.resverlogix.com

For further information: Theresa Kennedy, VP, CorporateCommunications, Resverlogix Corp., Phone: +1-604-538-7072, Email:Theresa@resverlogix.com; Sarah Zapotichny, Manager, InvestorRelations, Resverlogix Corp., Phone: +1-403-254-9252, Email:Sarah@resverlogix.com

ots Originaltext: Resverlogix Corp.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email: Sarah@resverlogix.com

Resverlogix Corp.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Phase 1b/2a Program Commences for RVX-208